Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...
Generally speaking, I’m not a big fan of discussing biopharmaceutical firms such as Gilead Sciences (NASDAQ:GILD). While the sector is intriguing and offers bountiful opportunities, it’s also replete ...
According to Benzinga Pro, Gilead Sciences Inc's peer group average for short interest as a percentage of float is 6.89%, which means the company has less short interest than most of its peers. Did ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback